Spontaneous Bacterial Peritonitis (SBP)

Bailey DeCoursey


Background

  • Infection of ascitic fluid without evidence of a surgical intra-abdominal source
  • Present in approximately 1/3 of patients with cirrhosis who are hospitalized
  • Presentation: fever, abdominal pain, encephalopathy, renal failure, acidosis, and/or leukocytosis. However, up to one‐third of the patients with spontaneous infections may be entirely asymptomatic or present with only encephalopathy and/or AKI
  • Pathophysiology: Combination of GI bacterial flora overgrowth, reduced liver protein production (low complement levels), impaired phagocytic cell function leading to inability to clear pathogens

Evaluation

  • Any pt with cirrhosis and ascites who is admitted should have diagnostic para to r/o SBP. Delaying paracentesis > 12 hours is associated with a 2.7-fold increase in mortality.
    • Obtain cell count with diff
    • Calculate the PMNs: total nucleated cells x % neutrophils.
    • PMN > 250 cells is diagnostic of SBP. If there are greater than 100k RBCs, you should correct for them: for every 250 RBCs, subtract 1 PMN
  • A positive ascitic bacterial culture with PMN <250 is called bacterascites and asymptomatic patients with bacterascites should NOT receive antibiotics as it is likely a contaminant (however, repeat paracentesis should be performed to exclude progression to SBP). You will also frequently see culture-negative SBP (neutrocytic ascites) which SHOULD be treated (see below).

Management

  • Immediately start empiric antibiotics
    • Guidelines recommend cefotaxime IV 2gm q8 hours x 5 days, but we commonly use ceftriaxone IV 2g q24h for 5-7 days at VUMC and Nashville VA
      • Most common culprits (E. coli, Klebsiella, streptococcal species, staphylococcal species)
      • If SBP developed with recent hospital admission (90 days), recent exposure to BSA, diagnosed >48 hours of admission, or with sepsis, should give zosyn +/- vanc if prior infection or positive swab for MRSA. Daptomycin should be added with hx of VRE infection instead of vanc.
      • Finally, in patients with current or recent exposure to zosyn consider meropenem for MDR coverage.
  • IV albumin 1.5 g/kg on day 1 and 1g/kg on day 3
  • NSBB do not need to be discontinued in patients with SBP unless hypotensive (mean arterial pressure <65mmHg). If stopped, the timing of re-initiation is based on recovery of blood pressure
  • PPI’s ↑ risk for SBP in pts with cirrhosis, and should be reviewed for appropriateness
  • Repeat diagnostic paracentesis two days after antibiotics initiated\
    • If <25% decrease in PMNs, antibiotics should be broadened. Consider secondary bacterial peritonitis.
  • Prophylaxis:
    • Ciprofloxacin 500mg BID (preferred) or Bactrim one DS tablet BID x 5-7 days
    • IV ceftriaxone 1g daily is currently the recommended antibiotic in patients with hemorrhage
  • Outpatient lifelong prophylaxis:
    • Prior SBP
    • Ascitic protein <1.5 AND Child Pugh >9 and bilirubin >3 OR Renal dysfunction (Cr >1.2, Na <130, or BUN >25)
    • Preferred: Bactrim DS tab daily or ciprofloxacin 500mg daily
    • Alternatives: cefdinir 300mg daily, Augmentin 875/125 daily
  • If suspicion is high for secondary bacterial peritonitis:
    • Examine serum-ascites albumin gradient (SAAG). SBP develops in pts with portal hypertension, defined by SAAG > 1.1 g/dL. SBP is unlikely if SAAG is < 1.1 g/dL.
    • While not particularly sensitive, an ascitic leukocyte count of 5-10k should prompt consideration of secondary peritonitis
    • Amylase from fluid can also be helpful to point towards pancreatic ascites, while bilirubin can indicate gallbladder perforation.
    • Peritoneal fluid CEA and alkaline phosphatase can additionally help identify hollow viscus injury.
    • Evaluate with cross-sectional imaging and surgical consultation as appropriate
    • Runyon’s Criteria to distinguish, requires 2/3 criteria below (protein, glucose, LDH)

Spontaneous

Secondary

Protein (g/dL) < 1 > 1
Glucose (mg/dL) ≥50 < 50
LDH (U) Elevated, but < 225 > 225
Organisms 0-1 Polymicrobial

Last updated on